HL: to what extent does bleomycin pulmonary toxicity affect outcomes?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In patients with Hodgkin's lymphoma (HL), neither bleomycin pulmonary toxicity (BPT) nor bleomycin discontinuation had a meaningful negative effect on survival outcomes.

Why this matters

  • Patients receiving bleomycin-containing chemotherapy are at significant risk for morbidity and mortality as a result of BPT.

Study design

  • Study to investigate incidence, risk factors, and outcomes associated with BPT in 253 patients with HL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine combination (ABVD) therapy.
  • Funding: None disclosed.

Key results

  • 11% overall incidence of BPT.
  • 26% of patient...